GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (FRA:6XY) » Definitions » EV-to-EBITDA

HBM Holdings (FRA:6XY) EV-to-EBITDA : 73.81 (As of May. 31, 2025)


View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, HBM Holdings's enterprise value is €704.27 Mil. HBM Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €9.54 Mil. Therefore, HBM Holdings's EV-to-EBITDA for today is 73.81.

The historical rank and industry rank for HBM Holdings's EV-to-EBITDA or its related term are showing as below:

FRA:6XY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.23   Med: 0.49   Max: 79.8
Current: 79.62

During the past 7 years, the highest EV-to-EBITDA of HBM Holdings was 79.80. The lowest was -16.23. And the median was 0.49.

FRA:6XY's EV-to-EBITDA is ranked worse than
91.55% of 497 companies
in the Biotechnology industry
Industry Median: 8.25 vs FRA:6XY: 79.62

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-31), HBM Holdings's stock price is €0.97. HBM Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.004. Therefore, HBM Holdings's PE Ratio (TTM) for today is 242.50.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


HBM Holdings EV-to-EBITDA Historical Data

The historical data trend for HBM Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings EV-to-EBITDA Chart

HBM Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial -2.30 -4.12 -1.45 3.46 7.04

HBM Holdings Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.45 - 3.46 - 7.04

Competitive Comparison of HBM Holdings's EV-to-EBITDA

For the Biotechnology subindustry, HBM Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HBM Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where HBM Holdings's EV-to-EBITDA falls into.


;
;

HBM Holdings EV-to-EBITDA Calculation

HBM Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=704.271/9.542
=73.81

HBM Holdings's current Enterprise Value is €704.27 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €9.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HBM Holdings  (FRA:6XY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

HBM Holdings's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.97/0.004
=242.50

HBM Holdings's share price for today is €0.97.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.004.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


HBM Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of HBM Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


HBM Holdings Business Description

Traded in Other Exchanges
Address
218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

HBM Holdings Headlines

No Headlines